FDA Calendar November Stocks: Turkeys or a Happy Thanksgiving?
On 10/19/09, BioElectronics (OTC: BIEL.PK) announced the initial results from the pilot section of its ongoing acetaminophen comparison study.
human genome sciences
Building a Better Anthrax Vaccine
Swine flu may be causing a current panic, but eight years ago, our big concern was anthrax.
Another Company Announces Positive Lupus Drug Data
Immunomedics has become the second biopharmaceutical company in recent weeks to announce a successful trial of its lupus drug.
Human Genome’s Lupus Drug Surprises Analysts
Shares in Human Genome Sciences increased by 277 percent on Monday after the company announced that their lupus drug Benlysta succeeded in a Phase III clinical trial.
Researchers Identify Lupus Trigger
Researchers identified three proteins, called Toll-Like Receptors (TLRs), that can cause the immune system to turn against the body.
Positive Results for Human Genome’s Lupus Drug Benlysta
Biotechnology company Human Genome Sciences reported that its drug candidate Benlysta reduced symptoms of lupus in a long-term clinical trial.